Margaret H. Collins, MD

Loading...

Staff Pathologist, Division of Pathology
Director, GI Pathology
Professor, UC Department of Pathology and Laboratory Medicine
UC Department of Pediatrics

margaret.collins@cchmc.org
Board Certified

About

Biography

I belong to a community of researchers at Cincinnati Children’s Hospital Medical Center, plus other institutions here and abroad, who are unwaveringly committed to finding cures for pediatric gastrointestinal (GI) diseases, including eosinophilic gastrointestinal disorders (EGID). This is especially important to me after meeting patients and their caregivers, witnessing the impact that EGID has on their lives and sharing their hope for a Food and Drug Administration (FDA)-approved therapy.

My research strives to improve diagnostic methods for children with GI diseases, such as EGID and inflammatory bowel disease. As a pediatric pathologist at Cincinnati Children’s, I help evaluate the efficacy of various therapies, including biologics, for pediatric patients who have EGID. I also participate in multi-institutional studies of pediatric inflammatory bowel disease.

I helped create the eosinophilic esophagitis histology scoring system (EoEHSS), which systematically evaluates esophageal biopsies obtained for eosinophilic esophagitis, the most common form of EGID. Some of the features evaluated correlate with symptoms and potentially provide new therapeutic endpoints.

Beginning in 2011, U.S. News & World Report named me one of the Top Doctors in Pathology. In 2020, I received the American Academy of Asthma, Allergy and Immunology (AAAAI) and American Partnership for Eosinophilic Disorders (APFED) award for the best EGID abstract at the AAAAI annual meeting.

Interests

Pediatric gastrointestinal pathology; eosinophilic gastrointestinal diseases; biopsy analyses; primary study endpoints; novel therapies to treat eosinophilic esophagitis in children; disorders of bowel immunity; bowel motility disorders

Services and Specialties

Research Areas

Publications

Long-term Safety and Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis: A 4-Year, Phase 3, Open-Label Study. Dellon, ES; Katzka, DA; Mukkada, VA; Collins, MH; Falk, GW; Richmond, CA; Terreri, B; Thakur, M; Boules, M; Goodwin, B; Hirano, I. Clinical Gastroenterology and Hepatology. 2025; 23:2155-2166.e5.

Langzeitbehandlung mit Dupilumab erhält histologische und endoskopische Verbesserungen bei Kindern mit eosinophiler Ösophagitis (EoE) aufrecht: Ergebnisse der offenen Verlängerungsstudie (OLE) der Studie EoE KIDS nach 100 Wochen. Chehade, M; Dellon, ES; Pesek, RD; Collins, MH; Ashok, D; Hörning, A; Liu, R; Louisias, M; Radin, A. Zeitschrift für Gastroenterologie. 2025; 63:e404.

Dupilumab normalisiert die wichtigsten histopathologischen Merkmale der eosinophilen Ösophagitis bei Erwachsenen und Jugendlichen: Post-Hoc-Analyse der Phase-III-Studie LIBERTY EoE TREET. Collins, MH; Gonsalves, N; Ashok, D; Turner, KO; Schilling, D; Xia, C; Zaghloul, S; Raphael, BP; Angello, JT; Radwan, A. Zeitschrift für Gastroenterologie. 2025; 63:e403-e404.

Patient-Reported Outcome Scores Are Comparable in Multiregional Versus Uniregional Eosinophilic Esophagitis. Collins, MH; Pan, Z; Yang, GY; Arva, NC; Pletneva, MA; Martin, LJ; Aceves, S; Chehade, M; Dellon, ES; Spergel, JM; Leung, J; Katzka, DA; Furuta, GT; Rothenberg, ME. Gastro Hep Advances. 2025; 4:100753.

Effect of Esophageal Dilation History on Efficacy Outcomes in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension. Hirano, I; Collins, MH; Katzka, DA; Mukkada, VA; Falk, GW; Terreri, B; Boules, M; Zhang, W; Desai, NK; Dellon, ES. The American Journal of Gastroenterology (Elsevier). 2025; 120:1502-1510.

Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trial. Dellon, ES; Collins, MH; Bredenoord, AJ; Philpott, H; Biedermann, L; Dulcine, M; Nguyen-Cleary, T; Su, C; Yu, J; Tan, H; Wang, W; Clax, P; Woolcott, JC; Hirano, I. The Lancet Gastroenterology and Hepatology. 2025; 10:622-633.

Circulating and Magnetic Resonance Imaging Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease. Dillman, JR; Tkach, JA; Fletcher, JG; Bruining, DH; Lu, A; Kugathasan, S; Alazraki, AL; Knight-Scott, J; Stidham, RW; Adler, J; Anton, CG; Imbus, RA; Dudley, JA; Denson, LA. Inflammatory Bowel Diseases. 2025; 31:1380-1391.

298: LONG-TERM DUPILUMAB MAINTAINS HISTOLOGIC AND ENDOSCOPIC IMPROVEMENTS IN CHILDREN WITH EOSINOPHILIC ESOPHAGITIS (EOE): 100-WEEK RESULTS FROM THE OPEN-LABEL EXTENSION (OLE) OF THE EOE KIDS STUDY. Chehade, M; Dellon, ES; Pesek, R; Collins, MH; Ashok, D; Liu, R; Louisias, M; Radin, A. Gastroenterology. 2025; 169:s-84.

One-food versus 4-food elimination diet for pediatric eosinophilic esophagitis: A multisite randomized trial. Kliewer, KL; Abonia, JP; Aceves, SS; Atkins, D; Bonis, PA; Capocelli, KE; Chehade, M; Collins, MH; Dellon, ES; Fei, L; Sun, Q; Wechsler, JB; Yang, GY; Rothenberg, ME. Journal of Allergy and Clinical Immunology. 2025; 155:520-532.

Dupilumab Improves Histopathologic Features in Patients With Eosinophilic Esophagitis: LIBERTY EoE TREET Study Results. Collins, MH; Rothenberg, ME; Dellon, ES; Bredenoord, AJ; Hirano, I; Leung, J; Sun, X; Glotfelty, L; Shabbir, A. Gastro Hep Advances. 2025; 4:100646.

From the Blog

Research Annual Report 2024

Tale of Two Studies Shows Mixed Progress Against EoE

Margaret H. Collins, MD, Marc E. Rothenberg, MD, PhD6/26/2024

Asthma and Allergy

Artificial Intelligence Holds the Key to Diagnosing Rare Esophageal Food Allergy Disease

Margaret H. Collins, MD, Marc E. Rothenberg, MD, PhD10/25/2021

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

Loading ...